Literature DB >> 18795299

Comparison of MRI (including SS SE-EPI and SPIO-enhanced MRI) and FDG-PET/CT for the detection of colorectal liver metastases.

Kenneth Coenegrachts1, Frank De Geeter, Leon ter Beek, Natascha Walgraeve, Shandra Bipat, Jaap Stoker, Hans Rigauts.   

Abstract

Fluoro-18-deoxyglucose positron emission tomography computed tomography (FDG-PET/CT) and magnetic resonance imaging (MRI), including unenhanced single-shot spin-echo echo planar imaging (SS SE-EPI) and small paramagnetic iron oxide (SPIO) enhancement, were compared prospectively for detecting colorectal liver metastases. Twenty-four consecutive patients suspected for metastases underwent MRI and FDG-PET/CT. Fourteen patients (58%) had previously received chemotherapy, including seven patients whose chemotherapy was still continuing to within 1 month of the PET/CT study. The mean interval between PET/CT and MRI was 10.2+/-5.2 days. Histopathology (n=18) or follow-up imaging (n=6) were used as reference. Seventy-seven metastases were detected. In nine patients, MRI and PET/CT gave concordant results. Sensitivities for unenhanced SS SE-EPI, MRI without SS SE-EPI and FDG-PET/CT were, respectively, 100% (p=9 x 10(-10) vs PET, p=8 x 10(-3) vs MRI without SS SE-EPI), 90% (p=2 x 10(-7) vs PET) and 60%. PET/CT sensitivity dropped significantly with decreasing size, from 100% in lesions larger than 20 mm (identical to MRI), over 54% in lesions between 10 and 20 mm (p=3 x 10(5) versus unenhanced SS SE-EPI), to 32% in lesions under 10 mm (p=6 x 10(-5) versus unenhanced SS SE-EPI). Positive predictive value of PET was 100% (identical to MRI). MRI, particularly unenhanced SS SE-EPI, has good sensitivity and positive predictive value for detecting liver metastases from colorectal carcinoma. Its sensitivity is better than that of FDG-PET/CT, especially for small lesions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18795299     DOI: 10.1007/s00330-008-1163-y

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  30 in total

1.  The use of FDG-positron emission tomography for the evaluation of colorectal metastases of the liver.

Authors:  K N Boykin; G B Zibari; D L Lilien; R W McMillan; D F Aultman; J C McDonald
Journal:  Am Surg       Date:  1999-12       Impact factor: 0.688

2.  Usefulness of intraoperative sonography for revealing hepatic metastases from colorectal cancer in patients selected for surgery after undergoing FDG PET.

Authors:  Bartosz Rydzewski; Farrokh Dehdashti; Brigid A Gordon; Sharlene A Teefey; Steven M Strasberg; Barry A Siegel
Journal:  AJR Am J Roentgenol       Date:  2002-02       Impact factor: 3.959

3.  Hepatic lesion detection: comparison of MR imaging after the administration of superparamagnetic iron oxide with dual-phase CT by using alternative-free response receiver operating characteristic analysis.

Authors:  J Ward; K S Naik; J A Guthrie; D Wilson; P J Robinson
Journal:  Radiology       Date:  1999-02       Impact factor: 11.105

4.  18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer.

Authors:  Giuseppe Lucio Cascini; Antonio Avallone; Paolo Delrio; Cesare Guida; Fabiana Tatangelo; Pietro Marone; Luigi Aloj; Francesco De Martinis; Pasquale Comella; Valerio Parisi; Secondo Lastoria
Journal:  J Nucl Med       Date:  2006-08       Impact factor: 10.057

5.  Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study.

Authors:  T J M Ruers; B S Langenhoff; N Neeleman; G J Jager; S Strijk; Th Wobbes; F H M Corstens; W J G Oyen
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

6.  The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver.

Authors:  D T Lai; M Fulham; M S Stephen; K M Chu; M Solomon; J F Thompson; D M Sheldon; D W Storey
Journal:  Arch Surg       Date:  1996-07

7.  The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver.

Authors:  H Zhuang; P Sinha; M Pourdehnad; P S Duarte; A J Yamamoto; A Alavi
Journal:  Nucl Med Commun       Date:  2000-09       Impact factor: 1.690

8.  Colorectal liver metastases: CT, MR imaging, and PET for diagnosis--meta-analysis.

Authors:  Shandra Bipat; Maarten S van Leeuwen; Emile F I Comans; Milan E J Pijl; Patrick M M Bossuyt; Aeilko H Zwinderman; Jaap Stoker
Journal:  Radiology       Date:  2005-08-11       Impact factor: 11.105

9.  Hepatic tumors: detection and characterization at 1-T MR imaging enhanced with AMI-25.

Authors:  A Denys; L Arrive; V Servois; B Dubray; D Najmark; A Sibert; Y Menu
Journal:  Radiology       Date:  1994-12       Impact factor: 11.105

10.  Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver.

Authors:  J V Vitola; D Delbeke; M P Sandler; M G Campbell; T A Powers; J K Wright; W C Chapman; C W Pinson
Journal:  Am J Surg       Date:  1996-01       Impact factor: 2.565

View more
  16 in total

1.  Combining diffusion-weighted MRI with Gd-EOB-DTPA-enhanced MRI improves the detection of colorectal liver metastases.

Authors:  D-M Koh; D J Collins; T Wallace; I Chau; A M Riddell
Journal:  Br J Radiol       Date:  2011-12-13       Impact factor: 3.039

Review 2.  Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer.

Authors:  Jianmin Xu; Xinyu Qin; Jianping Wang; Suzhan Zhang; Yunshi Zhong; Li Ren; Ye Wei; Shaochong Zeng; Deseng Wan; Shu Zheng
Journal:  J Cancer Res Clin Oncol       Date:  2011-07-28       Impact factor: 4.553

Review 3.  Diagnostic accuracy and impact on management of (18)F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review.

Authors:  Anna Margherita Maffione; Egesta Lopci; Christina Bluemel; Francesco Giammarile; Ken Herrmann; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10-16       Impact factor: 9.236

4.  Complex Surgical Strategies to Improve Resectability in Borderline-Resectable Disease.

Authors:  Motaz Qadan; Michael I D'Angelica
Journal:  Curr Colorectal Cancer Rep       Date:  2015-08-18

5.  Neoadjuvant chemotherapy affects staging of colorectal liver metastasis--a comparison of PET, CT and intraoperative ultrasound.

Authors:  Johann Spatz; G Holl; J Sciuk; M Anthuber; H M Arnholdt; B Märkl
Journal:  Int J Colorectal Dis       Date:  2010-10-20       Impact factor: 2.571

Review 6.  Liver metastases: Contrast-enhanced ultrasound compared with computed tomography and magnetic resonance.

Authors:  Vito Cantisani; Hektor Grazhdani; Cristina Fioravanti; Maria Rosignuolo; Fabrizio Calliada; Daniela Messineo; Maria Giulia Bernieri; Adriano Redler; Carlo Catalano; Ferdinando D'Ambrosio
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

7.  Magnetic resonance imaging of the liver: New imaging strategies for evaluating focal liver lesions.

Authors:  Kenneth Coenegrachts
Journal:  World J Radiol       Date:  2009-12-31

8.  Indeterminate Findings on Oncologic PET/CT: What Difference Does PET/MRI Make?

Authors:  Tyler J Fraum; Kathryn J Fowler; Jonathan McConathy; Farrokh Dehdashti
Journal:  Nucl Med Mol Imaging       Date:  2016-02-22

Review 9.  Polymeric micelles in anticancer therapy: targeting, imaging and triggered release.

Authors:  Chris Oerlemans; Wouter Bult; Mariska Bos; Gert Storm; J Frank W Nijsen; Wim E Hennink
Journal:  Pharm Res       Date:  2010-08-20       Impact factor: 4.200

10.  Multifunctional Chitosan Magnetic-Graphene (CMG) Nanoparticles: a Theranostic Platform for Tumor-targeted Co-delivery of Drugs, Genes and MRI Contrast Agents.

Authors:  Chunyan Wang; Sowndharya Ravi; Ujjwala Sree Garapati; Mahasweta Das; Mark Howell; Jaya MallelaMallela; Subbiah Alwarapan; Shyam S Mohapatra; Subhra Mohapatra
Journal:  J Mater Chem B       Date:  2013-09-21       Impact factor: 6.331

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.